Congrats to the CEPR for obtaining an ANR funding for its SuccesS project !

Congrats to the CEPR for obtaining an ANR funding for its SuccesS project !

7 October 2022

The 'SuccesS' project led by the research Center for Respiratory Diseases (CEPR) UMR INSERM 1100 in Tours is focusing on the development of analogues and formulations based on succinate to fight respiratory infections induced by SARS-CoV-2 and influenza viruses. The emergence of pandemic respiratory viruses (e.g. the SARS-CoV-2 coronavirus, certain influenza A viruses (IAV), ..) is a major concern. There is currently no effective anti-SARS-CoV-2 antiviral drug and the effectiveness of anti-IAV antivirals is disputed. Vaccination is in theory the best preventive strategy. However, antigenic drift of IAVs may reduce vaccine efficacy. The reluctance of some people to anti-SARS-CoV-2 vaccination is an additional obstacle.

This ANR project therefore aims to develop an innovative intrapulmonary metabolic therapy against these two viruses, based on (i) the fact that the metabolites are now recognised as key effectors of the antimicrobial response and (ii) the identification by the CEPR of two metabolites with anti-IAV and anti-SARS-CoV2 antiviral activity.

Project coordinator : M. Si-Tahar si-tahar@univ-tours.fr 

Modification date : 31 July 2023 | Publication date : 07 October 2021 | Redactor : Morgane Delavergne